MJ-26 is an inhibitor targeting Menin, characterized by a high binding affinity (Ki: 0.56 µM) and significant antiproliferative activity. It functions by inhibiting Menin-MLL interaction and promoting the degradation of Menin protein. MJ-26 demonstrates notable antitumor effects against acute myeloid leukemia (AML) and is applicable for AML research.
Target:
Epigenetic Reader Domain
* VAT and and shipping costs not included. Errors and price changes excepted
